title: Reboxetine in therapy-resistant enuresis: results and pathogenetic implications.
abstract: OBJECTIVE
  To investigate whether the norepinephrine reuptake inhibitor reboxetine is effective as a non-cardiotoxic alternative to imipramine in the treatment of therapy-resistant enuresis.
  
  
  METHODS
  Twenty-two children with severely socially handicapping enuresis resistant to urotherapy, the enuresis alarm, desmopressin and anticholinergics (all children had tried all these treatments) were given reboxetine, 4-8 mg at bed-time, for compassionate reasons.
  
  
  RESULTS
  Thirteen of the children (59%) achieved complete dryness with reboxetine, either as monotherapy or combined with desmopressin. Side-effects were minor and did not lead to discontinuation of treatment.
  
  
  CONCLUSIONS
  Although the results of this study need to be confirmed in randomized, placebo-controlled trials, reboxetine may prove to be a useful treatment for therapy-resistant nocturnal enuresis.
authors.affiliation: Department of Women's and Children's Health, Uppsala University Children's Hospital, Uppsala, Sweden. tryggve.neveus@kbh.uu.se
authors.forename: Tryggve
authors.initials: T
authors.lastname: Nevéus
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D015331:Cohort Studies; D000013:Congenital Abnormalities / Q000175:diagnosis; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage; D019988:Children with Disabilities; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004775:Enuresis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007099:Imipramine / Q000008:administration & dosage; D008297:Male; D009025:Morpholines / Q000008:administration & dosage* / Q000009:adverse effects; D011336:Probability; D011446:Prospective Studies; D011788:Quality of Life; D000077593:Reboxetine; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D009025:Morpholines; D000077593:Reboxetine; D003894:Deamino Arginine Vasopressin; D007099:Imipramine